Portfoliotracker

Nkarta, Inc.

NKTX · NASDAQGS · Healthcare Biotechnology 7/100 E

1,210 $
▲ +0,020 (+1,68 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 11:55
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score7 / 100 Market cap90,3 mil. $ P/E– Forward P/E-0,8 P/S– P/B0,4 EV/EBITDA– Dividend yield– FCF yield-113,28 % EPS-1,73 $ Net margin0,0 % Return on equity-46,6 % Beta1,26 Debt / equity0,33
52-week range 1,11 to 3,72
3-month average volume1,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Employees
103
Country
United States
Fiscal year end
31. 12.
Data since
10. 7. 2020

Explore further

Similar companies ALXOBDTXCCCCFDMT

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account